Local consolidative therapy (LCT) for selective oligometastatic cancers

Trial ID:
IRB-20-7507
Patrick W Linson, MD, MPH
The goal of this study is to learn if giving local consolidative therapy (LCT) up-front can better help to control oligometastatic disease, compared to a strategy of closely monitoring patients and waiting to give LCT at a later time point. LCT includes surgery, radiation, or other interventions.
* Have had no more than 4 prior lines of systemic therapy administered to treat metastatic disease<br>* Be 18 years of age on the day of signing informed consent<br>* Have pathology confirmed diagnosis of cancer (Oligometastatic solid tumors)

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org